About - Abond CRO - Biostatistical Analysis – Phase I Clinical Trial Development

Trusted by Sponsors
Since 1974

Here at Abond CRO (formerly known as QST Consultations), our belief in partnering to improve healthcare has led to decades of success. Talk to our long-standing clients and they’ll tell you that we’re not a vendor, we’re a part of their team. That our relationship is seamless and collaborative, and our contributions authoritative and trusted.

Today we serve universities, medical device manufacturers and pharmaceutical companies, delivering the expertise and personalized service needed to advance healthcare. Because we understand that each trial is unique, our staff leverages our years of technical expertise to tailor our solution to the specific needs of each client — from startups to multinational life sciences organizations.

Our Core Principles

HONESTY

We value the truth above all else and seek it continually.

FOCUS

We keep the big picture in mind while sweating every detail.

RESPONSIBILITY

We take pride in our work and own every decision.

Secure, Custom-built Facilities

In January of 2010 we moved into our central facility, specially designed for safety and data security after in-depth consultation with our sponsors, IT professionals, geothermal heating experts, and structural engineers. Our state-of-the-art computing system supports clients 24/7, protecting the confidentiality and integrity of client data.

Our Leadership Team

Phil Doren, PhDCEO & Vice President

Dr. Phil Doren is responsible for expanding the company’s service offerings, corporate leadership, risk mitigation, cultivating strategic business opportunities, fostering our well-renowned industry reputation and developing leaders within the organization. Phil has over 25 years of experience in developing and managing partnerships in the CRO industry. He is a decisive leader who has been successful in improving product development programs through high quality data collections completed in reduced time frames.

John Quiring, PhDFounder & Chief Science Officer

John is principally a scientist and has applied his statistical education interactively with clients/sponsors, regulatory officials, and co-workers with the goal of advancing the availability of medical products for over 40 years. As founder of QST, the predecessor name of Abond CRO Inc., he spearheaded the approval of over 90 regulatory submissions participating in strategic FDA / sponsor meetings, performing statistical analyses as well as directing the company’s work efforts. He has served as CEO and is now the Chief Scientific Officer and a member of the Board of Directors.

Zoran Antonijevic, MSVice President, Statistical Consulting

Zoran Antonijevic is Vice President, Statistical Consulting at Abond CRO Inc. He has held executive and innovation leadership positions in pharmaceutical companies and CROs and has designed more than 100 clinical trials in numerous therapeutic areas, many of which included adaptive designs. Zoran is a long-time Chair and leader of the DIA Adaptive Design Scientific Working Group. He has authored numerous papers and scientific presentations and is editor of the books “Optimization of Pharmaceutical R&D Programs and Portfolios” and “Platform Trials in Drug Development”.

Brian Armstrong, MSSenior Director of Clinical Data Standards & Statistical Programming

Brian’s broad experience encompasses a multitude of successful drug and device submissions to regulatory authorities, providing the essential skills for keeping Abond in compliance with regulatory data collection and submission requirements. With Brian’s high attention to detail, he helps our clients navigate the complex clinical data environment.

Mary DeWeerd, MBAAssistant Director, Human Resources

Mary DeWeerd has experience in all areas of human resources. Mary is responsible for employee relations, onboarding, full-cycle recruiting, benefit administration, supervisor training and development, compensation, and record keeping. Mary works with personnel, across all departments, in an energetic manner that is friendly, helpful and a pleasure to encounter.

Tami BullenAssociate Director, Data Management

Tami Bullen has worked in and managed the Data Management Department for 28 years at Abond CRO Inc. During that time, she has worked on studies of more than 30 indications across 12 therapeutic areas. Tami has worked in over 10 different clinical database systems and holds 19 professional certifications. Tami earned her Bachelor of Science in mathematics from Grand Valley State University.

Our Board of Directors

John Quiring, PhDChairman

John is principally a scientist and has applied his statistical education interactively with clients/sponsors, regulatory officials, and co-workers with the goal of advancing the availability of medical products for over 40 years. As founder of QST, the predecessor name of Abond CRO Inc., he spearheaded the approval of over 90 regulatory submissions participating in strategic FDA / sponsor meetings, performing statistical analyses as well as directing the company’s work efforts. He has served as CEO and is now the Chief Scientific Officer and a member of the Board of Directors.

Phil Doren, PhDDirector

Dr. Phil Doren is responsible for expanding the company’s service offerings, corporate leadership, risk mitigation, cultivating strategic business opportunities, fostering our well-renowned industry reputation and developing leaders within the organization. Phil has over 25 years of experience in developing and managing partnerships in the CRO industry. He is a decisive leader who has been successful in improving product development programs through high quality data collections completed in reduced time frames.

Jason Proos, MSDirector

Jason Proos joined QST (now Abond) in 1999. Jason is responsible for planning, designing, purchasing, installing, monitoring, operating, and maintaining Abond’s IT infrastructure. Jason earned his Masters of Science in Statistics from Western Michigan University.

Susan Walker, MD, FAADDirector

Dr. Walker is an independent consultant and the immediate past director of the Division of Dermatology and Dental Products (DDDP) at the US Food and Drug Administration (FDA). She led this division with responsibilities for review and approval of regulatory applications, including New Drug Applications, Biologics Licensing Applications, Investigational New Drug Applications, labeling supplements, Pediatric Study Plans, Risk Evaluation and Mitigation Strategies, and other submissions. During her tenure as Division Director she led the regulatory approval of dermatology products in the transition from a primarily topical focus to the current broader focus; the introduction of systemic biologic agents.

Dr. Walker currently provides independent consulting services as Susan J. Walker Consulting, LLC., that cover product development and regulatory advice to US and international clients in the pharmaceutical and device industry.

Join Our Team

See Openings

Trusted by Sponsors Since 1974